Rise in prevalence of rheumatoid arthritis is fueling the rheumatology therapeutics market size. Non-steroidal Anti-Inflammatory Agents (NSAIDs), corticosteroids, and Disease Modifying Anti-rheumatic Drugs (DMARDs) are widely employed in the treatment of rheumatic diseases and musculoskeletal disorders.
R&D of disease-modifying therapies and personalized medicine approaches in rheumatoid arthritis therapy is driving the rheumatology therapeutics market expansion. DMARDs help reduce the signs and symptoms of rheumatoid arthritis and can influence the progression of tissue destruction.
Better understanding of individual genetics is likely to offer lucrative rheumatology therapeutics market opportunities to vendors. Vendors are developing combination therapies to combat complex immune-mediated diseases by delivering two therapies in one package.
Rheumatology is the medical science devoted to rheumatic diseases and musculoskeletal disorders. It is the study of autoimmune diseases and connective tissue diseases. Osteoarthritis, rheumatoid arthritis, seronegative spondyloarthropathy, crystal-induced arthritis, systemic lupus erythematosus, and vasculitis are various types of rheumatologic diseases.
Rheumatic diseases are most common in people older than 50 years of age. Age, obesity, occupation, and history are some of the risk factors for these diseases.
Rheumatology therapeutics include Disease Modifying Anti-rheumatic Drugs (DMARDs), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), corticosteroids, and uric acid drugs. Conventional DMARDs include Azathioprine, Ciclosporin, Cyclophosphamide, Gold (Myocrisin IM or auranofin oral), and Hydroxychloroquine (HCQ).
| Attribute | Detail |
|---|---|
| Drivers |
|
Rheumatoid arthritis (RA) is the most common inflammatory arthritis, with an estimated 17·6 million people suffering from the disease worldwide. The age-standardized global prevalence rate was 208·8 cases per 100,000 population, representing a 14·1% increase since 1990, according to a study published in The Lancet Rheumatology in 2023.
RA affects people worldwide and affects females more frequently than males, with a female: male ratio of over 3:1. The disease most commonly occurs at age 45-65 years although it can occur at any age -occurring as a distinct disease in childhood. Thus, increase in prevalence of RA is propelling the rheumatology therapeutics market value.
Elderly onset rheumatoid arthritis (EORA) is rheumatoid arthritis (RA) that develops at an older age. About 70% of people living with rheumatoid arthritis are women, and 55% are older than 55 years.
Geriatric syndromes, such as cognitive impairment, depression, falls, urinary incontinence, and malnutrition are more prevalent in older patients with RA than in younger patients with the disease. Hence, rise in geriatric population is expected to spur the rheumatology therapeutics market growth in the near future.
Vendors in the global rheumatology therapeutics market are developing novel approaches to restore immune system function by targeting regulatory networks.
In November 2023, Mozart Therapeutics, a developer of CD8 Treg Modulators for the treatment of autoimmune and inflammatory diseases, presented preclinical pharmacology and tolerability data for MTX-101, a CD8 Treg modulator at the annual meeting of the American College of Rheumatology held in San Diego, U.S. According to the company, the study data collectively supports the therapeutic potential of MTX-101 for the treatment of autoimmunity including rheumatological diseases.
Similarly, Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, presented the first public data for three novel therapeutic approaches - the receptor-interacting protein kinase 2 (RIPK2) and interleukin-1 receptor-associated kinase 4 (IRAK4) scaffolding inhibitors, and tumor necrosis factor receptor-2 (TNFR2) agonist for regulatory T (Treg) cell modulation - to treat large populations with underserved inflammatory and autoimmune diseases. Thus, R&D of disease-modifying therapies is boosting the rheumatology therapeutics market demand.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
According to the latest rheumatology therapeutics market analysis, North America held largest share in 2023. Rise in prevalence of inflammatory and autoimmune diseases is fueling the market dynamics of the region. Arthritis is a serious health crisis.
The Centers for Disease Control and Prevention estimates that 1 in 5 (or 53.2 million) adults in the U.S. have some form of arthritis. While there are estimated to be more than 100 types of arthritis, osteoarthritis (OA) is the most common form of arthritis, affecting 32.5 million adults in the country.
Approval and launch of new drugs is boosting the rheumatology therapeutics market share in North America. In 2023, The U.S. Food and Drug Administration approved abatacept (Orencia) for the treatment of active psoriatic arthritis (PsA) in patients aged ≥2 years.
Psoriatic arthritis is a form of juvenile idiopathic arthritis (JIA) and is characterized by chronic joint inflammation and swelling, as well as an increased risk for asymptomatic eye inflammation.
Vendors in the rheumatology therapeutics market landscape are exploring ways to inhibit multiple disease pathways and enable greater precision through technologies such as Antibody Drug Conjugates (ADCs) and combination therapies.
Merck & Co., Inc., AbbVie, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Amgen, Inc., Genentech, Inc., Novartis AG, Johnson & Johnson Innovative Medicine, F. Hoffmann-La Roche AG, and Sanofi are players operating in this rheumatology therapeutics industry.
These companies have been profiled in the rheumatology therapeutics market report based on various parameters including company overview, business segments, product portfolio, recent developments, business strategies, and financial overview.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 48.8 Bn |
| Market Forecast (Value) in 2034 | US$ 65.1 Bn |
| Growth Rate (CAGR) | 2.6% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 48.8 Bn in 2023
It is anticipated to grow at a CAGR of 2.6% from 2024 to 2034
Rise in prevalence of rheumatoid arthritis and R&D of disease-modifying therapies
North America was the leading region in 2023
Merck & Co., Inc., AbbVie, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Amgen, Inc., Genentech, Inc., Novartis AG, Johnson & Johnson Innovative Medicine, F. Hoffmann-La Roche AG, and Sanofi
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Rheumatology Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Rheumatology Therapeutics Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Rheumatology Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2020-2034
6.3.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
6.3.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
6.3.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
6.3.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
6.3.3. Corticosteroids
6.3.4. Uric Acid Drugs
6.3.5. Others
6.4. Market Attractiveness, by Drug Class
7. Global Rheumatology Therapeutics Market Analysis and Forecast, by Disease Indication
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Indication, 2020-2034
7.3.1. Rheumatoid Arthritis
7.3.2. Osteoarthritis
7.3.3. Gout
7.3.4. Psoriatic Arthritis
7.3.5. Ankylosing Spondylitis
7.3.6. Others
7.4. Market Attractiveness, by Disease Indication
8. Global Rheumatology Therapeutics Market Analysis and Forecast, by Route of Administration
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2020-2034
8.3.1. Parenteral Route
8.3.2. Oral Route
8.3.3. Topical
8.4. Market Attractiveness, by Route of Administration
9. Global Rheumatology Therapeutics Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2020-2034
9.3.1. Hospital Pharmacy
9.3.2. Retail Pharmacy
9.3.3. Online Pharmacy
9.4. Market Attractiveness, by Distribution Channel
10. Global Rheumatology Therapeutics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Rheumatology Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2020-2034
11.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
11.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
11.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
11.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
11.2.3. Corticosteroids
11.2.4. Uric Acid Drugs
11.2.5. Others
11.3. Market Attractiveness, by Drug Class
11.4. Market Value Forecast, by Disease Indication, 2020-2034
11.4.1. Rheumatoid Arthritis
11.4.2. Osteoarthritis
11.4.3. Gout
11.4.4. Psoriatic Arthritis
11.4.5. Ankylosing Spondylitis
11.4.6. Others
11.5. Market Attractiveness, by Disease Indication
11.6. Market Value Forecast, by Route of Administration, 2020-2034
11.6.1. Parenteral Route
11.6.2. Oral Route
11.6.3. Topical
11.7. Market Attractiveness, by Route of Administration
11.8. Market Value Forecast, by Distribution Channel, 2020-2034
11.8.1. Hospital Pharmacy
11.8.2. Retail Pharmacy
11.8.3. Online Pharmacy
11.9. Market Attractiveness, by Distribution Channel
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Drug Class
11.11.2. By Disease Indication
11.11.3. By Route of Administration
11.11.4. By Distribution Channel
11.11.5. By Country
12. Europe Rheumatology Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2020-2034
12.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
12.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
12.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
12.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
12.2.3. Corticosteroids
12.2.4. Uric Acid Drugs
12.2.5. Others
12.3. Market Attractiveness, by Drug Class
12.4. Market Value Forecast, by Disease Indication, 2020-2034
12.4.1. Rheumatoid Arthritis
12.4.2. Osteoarthritis
12.4.3. Gout
12.4.4. Psoriatic Arthritis
12.4.5. Ankylosing Spondylitis
12.4.6. Others
12.5. Market Attractiveness, by Disease Indication
12.6. Market Value Forecast, by Route of Administration, 2020-2034
12.6.1. Parenteral Route
12.6.2. Oral Route
12.6.3. Topical
12.7. Market Attractiveness, by Route of Administration
12.8. Market Value Forecast, by Distribution Channel, 2020-2034
12.8.1. Hospital Pharmacy
12.8.2. Retail Pharmacy
12.8.3. Online Pharmacy
12.9. Market Attractiveness, by Distribution Channel
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Drug Class
12.11.2. By Disease Indication
12.11.3. By Route of Administration
12.11.4. By Distribution Channel
12.11.5. By Country/Sub-region
13. Asia Pacific Rheumatology Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2020-2034
13.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
13.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
13.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
13.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
13.2.3. Corticosteroids
13.2.4. Uric Acid Drugs
13.2.5. Others
13.3. Market Attractiveness, by Drug Class
13.4. Market Value Forecast, by Disease Indication, 2020-2034
13.4.1. Rheumatoid Arthritis
13.4.2. Osteoarthritis
13.4.3. Gout
13.4.4. Psoriatic Arthritis
13.4.5. Ankylosing Spondylitis
13.4.6. Others
13.5. Market Attractiveness, by Disease Indication
13.6. Market Value Forecast, by Route of Administration, 2020-2034
13.6.1. Parenteral Route
13.6.2. Oral Route
13.6.3. Topical
13.7. Market Attractiveness, by Route of Administration
13.8. Market Value Forecast, by Distribution Channel, 2020-2034
13.8.1. Hospital Pharmacy
13.8.2. Retail Pharmacy
13.8.3. Online Pharmacy
13.9. Market Attractiveness, by Distribution Channel
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Drug Class
13.11.2. By Disease Indication
13.11.3. By Route of Administration
13.11.4. By Distribution Channel
13.11.5. By Country/Sub-region
14. Latin America Rheumatology Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2020-2034
14.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
14.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
14.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
14.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
14.2.3. Corticosteroids
14.2.4. Uric Acid Drugs
14.2.5. Others
14.3. Market Attractiveness, by Drug Class
14.4. Market Value Forecast, by Disease Indication, 2020-2034
14.4.1. Rheumatoid Arthritis
14.4.2. Osteoarthritis
14.4.3. Gout
14.4.4. Psoriatic Arthritis
14.4.5. Ankylosing Spondylitis
14.4.6. Others
14.5. Market Attractiveness, by Disease Indication
14.6. Market Value Forecast, by Route of Administration, 2020-2034
14.6.1. Parenteral Route
14.6.2. Oral Route
14.6.3. Topical
14.7. Market Attractiveness, by Route of Administration
14.8. Market Value Forecast, by Distribution Channel, 2020-2034
14.8.1. Hospital Pharmacy
14.8.2. Retail Pharmacy
14.8.3. Online Pharmacy
14.9. Market Attractiveness, by Distribution Channel
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Drug Class
14.11.2. By Disease Indication
14.11.3. By Route of Administration
14.11.4. By Distribution Channel
14.11.5. By Country/Sub-region
15. Middle East & Africa Rheumatology Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Class, 2020-2034
15.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
15.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
15.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
15.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
15.2.3. Corticosteroids
15.2.4. Uric Acid Drugs
15.2.5. Others
15.3. Market Attractiveness, by Drug Class
15.4. Market Value Forecast, by Disease Indication, 2020-2034
15.4.1. Rheumatoid Arthritis
15.4.2. Osteoarthritis
15.4.3. Gout
15.4.4. Psoriatic Arthritis
15.4.5. Ankylosing Spondylitis
15.4.6. Others
15.5. Market Attractiveness, by Disease Indication
15.6. Market Value Forecast, by Route of Administration, 2020-2034
15.6.1. Parenteral Route
15.6.2. Oral Route
15.6.3. Topical
15.7. Market Attractiveness, by Route of Administration
15.8. Market Value Forecast, by Distribution Channel, 2020-2034
15.8.1. Hospital Pharmacy
15.8.2. Retail Pharmacy
15.8.3. Online Pharmacy
15.9. Market Attractiveness, by Distribution Channel
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Drug Class
15.11.2. By Disease Indication
15.11.3. By Route of Administration
15.11.4. By Distribution Channel
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. F. Hoffmann-La Roche Ltd.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. AbbVie, Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Pfizer, Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Takeda Pharmaceutical Company Limited
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Amgen, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Genentech, Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Novartis AG
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Johnson & Johnson Innovative Medicine
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Sanofi
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Merck & Co., Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Bristol-Myers Squibb Company
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
List of Tables
Table 01: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
Table 02: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
Table 03: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 04: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
Table 05: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Region, 2020-2034
Table 06: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020-2034
Table 07: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
Table 08: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
Table 09: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
Table 10: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 11: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 12: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
Table 13: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
Table 14: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
Table 15: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 16: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 17: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
Table 18: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
Table 19: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
Table 20: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 21: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
Table 23: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
Table 24: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
Table 25: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 26: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 27: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
Table 28: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
Table 29: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
Table 30: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
List of Figures
Figure 01: Global Rheumatology Therapeutics Market Size (US$ Mn), by Region, 2023 and 2034
Figure 02: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Drug Class, 2023
Figure 03: Global Rheumatology Therapeutics Market Value Share, by Drug Class, 2023
Figure 04: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Disease Indication, 2023
Figure 05: Global Rheumatology Therapeutics Market Value Share, by Disease Indication, 2023
Figure 06: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Route of Administration, 2023
Figure 07: Global Rheumatology Therapeutics Market Value Share, by Route of Administration, 2023
Figure 08: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2023
Figure 09: Global Rheumatology Therapeutics Market Value Share, by Distribution Channel, 2023
Figure 10: Global Rheumatology Therapeutics Market Value Share, by Region, 2023
Figure 11: Global Rheumatology Therapeutics Market Value (US$ Mn) Forecast, 2020-2034
Figure 12: Global Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 13: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 14: Global Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 15: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 16: Global Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 17: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 18: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2023
Figure 19: Global Rheumatology Therapeutics Market Value Share, by Distribution Channel, 2023
Figure 20: Global Rheumatology Therapeutics Market Value Share Analysis, by Region, 2023 and 2034
Figure 21: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
Figure 22: North America Rheumatology Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 23: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Country, 2024-2034
Figure 24: North America Rheumatology Therapeutics Market Value Share Analysis, by Country, 2023 and 2034
Figure 25: North America Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 26: North America Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 27: North America Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 28: North America Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 29: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 30: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 31: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 32: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 33: Europe Rheumatology Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 34: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 35: Europe Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 36: Europe Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 37: Europe Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 38: Europe Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 39: Europe Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 40: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 41: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 42: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 43: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 44: Asia Pacific Rheumatology Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 45: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 46: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 47: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 48: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 49: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 50: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 51: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 52: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 53: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 54: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2034
Figure 55: Latin America Rheumatology Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 56: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 57: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 58: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 59: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 60: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 61: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 62: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 63: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 64: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 65: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 66: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 67: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 68: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 69: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 70: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 71: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 72: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 73: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 74: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 75: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 76: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Rheumatology Therapeutics Market
